Menopause Relief Gets Major OB-GYN Update

A leading OB-GYN group has issued its first update in twelve years on managing disruptive menopause symptoms. Doctors are now stressing the importance of hormone therapies, noting recent FDA actions to ensure adequate supply. The American College of Obstetricians & Gynecologists (ACOG) detailed these recommendations this month.

Menopause, typically occurring around age 50, involves declining estrogen and progesterone. This can lead to significant vasomotor issues like hot flashes, sleep disruption, and depressive symptoms affecting many women. Previously, many women suffered silently, but there is a growing consensus that these symptoms warrant treatment.

Hormone therapy is now strongly supported as a first-line treatment for moderate to severe menopausal symptoms. While not for everyone, its benefits often outweigh risks for many. The FDA has removed safety warnings from many hormone treatments, reviving interest and increasing demand.

For those who cannot use or choose to avoid hormonal medications, several nonhormonal options are available. These include medications like fezolinetant and elinzanetant, which target temperature regulation. Certain antidepressants and non-drug treatments such as cognitive behavioral therapy and acupuncture also show promise.

Doctors urge patients to consult their OB-GYNs for personalized advice, emphasizing that numerous hormonal and nonhormonal options exist. This updated guidance aims to empower women to seek and receive effective relief for their menopause symptoms.